HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC Testimonial Guidelines Say Advertisers Must Show Typical Outcomes

This article was originally published in The Tan Sheet

Executive Summary

Revised Federal Trade Commission guidelines on endorsements and testimonials will not have a chilling effect on advertising as long as marketers using anecdotal testimonials provide information on what typical outcomes are, according to an FTC executive

You may also be interested in...



In Brief

Novartis appeals Excedrin case to NARB

FTC's endorsement guide to come later in 2009

The Federal Trade Commission will issue updated guides later in 2009 to assist advertisers in using endorsements. Agency staff is currently analyzing comments about proposed changes to its 1980 guides, said David Vladeck, director of FTC's Bureau of Consumer Protection (1"The Tan Sheet" Dec. 1, 2008). The current "guides are not working as intended to prevent consumer deception," particularly with "typicality claims," he told the Senate Consumer Protection, Product Safety, and Insurance Subcommittee July 22. Vladeck said testimonials and endorsements still are misused, particularly with weight-loss products

Supplements’ Direct Response Marketing Success Sets Off FTC Alarm

Dietary supplement firms could face more aggressive enforcement from the Federal Trade Commission as they take advantage of increased direct response marketing opportunities created by the recession

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS137318

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel